Electrotherapy medical device maker Zynex has received US Food and Drug Administration (FDA) clearance for its NexWave device.

The NexWave device is capable of delivering three modalities of stimulation: transcutaneous electrical nerve stimulation, interferential electrical stimulation and neuromuscular electrical stimulation.

Zynex CEO Thomas Sandgaard said that the combined modalities of the company’s NexWave provide doctors and clinicians a comprehensive pain therapy solution for their patients.

”We believe this new product is unique in the electrotherapy industry and provides our sales force with a competitive edge to fuel revenue generation in our already rapidly growing Zynex Medical subsidiary," Sandgaard added.